Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof

US9957240B2 · kind B2 · utility

Assignees

• CRYSTAL PHARMATECH CO., LTD. · CN
• SUZHOU PENGXU PHARMATECH CO. LTD. · CN

Inventors

• Minhua Chen · 安丰镇, CN
• Yanfeng Zhang · Suzhou, CN
• Chaohui Yang · Suzhou, CN
• Xiaoyu Zhang · Suzhou, CN
• Jiaoyang Li · Suzhou, CN
• Peng Wang · San Diego, US
• Pixu LI · Suzhou, CN

Key dates

• Filing date: Dec 8, 2015
• Grant date: May 1, 2018
• Expiry date: Dec 8, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3′-methyl-T-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.